This is a prospective, longitudinal, controlled study of cognitive function and fatigue in
patients with apparently localized CRC treated with adjuvant or neoadjuvant chemotherapy. In
addition to following each patient over time (i.e. acting as their own control), a separate
control group will consist of patients with early stage CRC (Stage A or B) who have had
surgical resection of their tumour, but who do not require adjuvant chemotherapy, or patients
with stage C CRC who have declined chemotherapy.
Also included is a smaller sub-study of patients with limited metastatic CRC who are treated
with more toxic chemotherapy
To compare changes in cognitive function, as compared to baseline assessment, of patients
with CRC who do, or do not, receive 5FU-based chemotherapy. The primary measures of cognitive
function are the High Sensitivity Cognitive Screen (HSCS) & Coghealth™.